About Me

Anita Szewczyk, MD is a renowned physician specializing in Medical Oncology and Hematology with special interest in Breast cancer, Gynecological malignancies, Benign Hematology as well as broad range of Hematological Malignancies. 

Her undergraduate education began at McMaster University in Canada where she graduated with Honors in Biology. Subsequently, she completed Medical School at Jagiellonian University in Cracow, Poland and finished her medical education Summa Cum Laude and accepted into the Internal Medicine Residency program in Pennsylvania at Pinnacle Health Hospitals.

After 3 years of internal medical training as a resident she was accepted into Hematology and Oncology Fellowship Program at Penn State Hershey Medical Center where she was awarded Chief Fellow in her class.

Currently, she is on staff at Ironwood Cancer and Research Centers in East Phoenix, Arizona, which is established and recognized as one of the best cancer centers in Western United States. 

Dr. Szewczyk is an author of many medical articles and numerous talks where she has educated patients in community about Breast Cancer and it's treatment, sexuality problems related to treatments, as well as nutrition and diet related to prevention of many forms of cancer.

She has maintained her consulting practice in Oncology and Hematology. She is Board Certified in Internal Medicine, Medical Oncology, and Hematology.

Her main influencing decision to write this blog was to help her patients navigate in a complex medical information era, where so much depends on what we know and how we decide which internet information is correct and truthful. Internet information is abundant but also very conflicting.

"What should I eat to help me fight my Cancer?"

"Is there any food that can help my immune system?"

"What can I eat to feel better during my treatments?"

"Is there any medical evidence that some cancers can be prevented by healthy nutrition?"

These are the number one questions her patients would ask in her clinic. After hearing them over and over again, the idea about creating website and blog on nutrition and diet related to Cancer was born.

Dr. Szewczyk dedicates this blog to all her patients and their families as a medical resource and guide.

Dr. Szewczyk presently resides in Phoenix area with her family. In a past 3 years Dr. Szewczyk was featured in Phoenix Magazine as “Top Doc”.


  • Board Certified in Medical Oncology 
  • Board Certified in Hematology 
  • Board Certified in Internal Medicine 



  • American Society of Clinical Oncology 
  • American Medical Association 



  • Epstein Barre Virus-Negative Diffuse Large B-Cell Lymphoma in an HIV-Infected Man with a Durable Complete Remission on Highly Active Antiretroviral Therapy Alone 
  • Southern Medical Journal: January 2010 - Volume 103 - Issue 1 - pp 76-80 
  • Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice 
  • J Oncol Pharm Pract. 2010 Aug 4; 20685771 



Abbott Protocol M10-301: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment (2009- ) 

Genentech Protocol TDM4370g/Roche Protocol BO21977: A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy (EMILIA) (2009- )

Novartis Protocol CRAD001Y2301: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole (BOLERO 2). (2009- ) 

Novartis Protocol CRAD001J2301: A Randomize Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO 1). (2009- ) 

Imclone Protocol CP12-0606/TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of iMC-1121 B Plus Docetaxel versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer. Protocol IMCL CP12-0606/TRIO-012. (2010 – 

Novartis Protocol CRADN2301: A Randomized Double-Blind, Placebo-Controlled, Multicenter phase III Study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy (PILLAR 2) (2010 – 

GlaxoSmith Kline Protocol LPT112515: A Randomized, Phase III, Open-Label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2-positive Metastatic Breast Cancer (HALT-MBC) (2010 – 

Peregrine Protocol PPHM 1001: A Randomized, Open-Label, Phase 2 Trial of Paclitaxel/Carboplatin With or Without Bavituximab in Patients with Previously Untreated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 – 

Peregrine Protocol PPHM 0902: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer. (2010 -